<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798785</url>
  </required_header>
  <id_info>
    <org_study_id>BK_TX_06</org_study_id>
    <nct_id>NCT00798785</nct_id>
  </id_info>
  <brief_title>Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients</brief_title>
  <official_title>Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ-VUB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present proof of concept study addresses the following specific aims:

      The general objectives of this work are:

        1. To increase and maintain the functional beta-cell mass after islet transplantation under
           a condition of low-dose tacrolimus

        2. To co-investigate the potential of alternative sites for encapsulated beta-cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Aim 1: To increase functional beta cell mass by adding rituximab at first implantation

        2. Aim 2: To increase functional beta cell mass by adding basilixumab at second
           implantation

        3. Aim 3: To assess the influence of down-tapering the tacrolimus dose during
           posttransplant years 2-5 on these data, on metabolic control, on the prevalence of
           hypoglycemia and on safety parameters.

        4. Aim 4: To investigate the potential of the peritoneum and omentum as an alternative site
           for encapsulated beta-cells.

        5. Aim 5: To investigate the potential of the brachioradial muscle as an alternative site
           for encapsulated beta-cells.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinically relevant beta cell graft function</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>group I ATG-MMF-TAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two clinical implants in the liver:
First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II ATG-Rituximab-MMF-TAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two clinical implants in the liver:
First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group III ATG-Basilixumab-MMF-TAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two clinical implants in the liver:
First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group IV omentum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two clinical implants: first in the omentum followed by a clinical implant in the liver:
First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-MMF-TAC</intervention_name>
    <description>ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver.</description>
    <arm_group_label>group I ATG-MMF-TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-Rituximab-MMF-TAC</intervention_name>
    <description>ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.</description>
    <arm_group_label>group II ATG-Rituximab-MMF-TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-basilixumab-MMF-TAC</intervention_name>
    <description>First transplantation:
ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Second transplantation:
Basilixumab:
the day before the second transplantation followed by 4days after transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver.</description>
    <arm_group_label>group III ATG-Basilixumab-MMF-TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>omentum</intervention_name>
    <description>Two clinical implants: first in omentum followed by a clinical implant in the liver:
In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels &gt;= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum.</description>
    <arm_group_label>group IV omentum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years, male or female, Caucasian or not; only subjects &lt; 50 yrs will be
             allocated to the rituximab treatment arm

          -  Body weight &lt; 100 kg; patients with a bodyweight of &lt; 80kg, will receive priority

          -  Patients with a BMI ≤ 27 kg/m2 will receive priority

          -  Type 1 insulin-dependent diabetes

          -  C-peptide &lt; 0.07 nmol/l (&lt;0.2 µg/l) 6 min. after glucagon IV (1mg) (glycemia &gt; 180
             mg/dl)

          -  Intensive insulin therapy for more than two years, patients with insulin pump during
             at least 2 months before inclusion will receive priority

          -  Patients should have at least one of the following chronic complications of diabetes:

               -  Plasma creatinine &lt;2 mg/dl and albuminuria 30-1000 mg/ 24hrs on 3 separate
                  determinations (&gt;1 month) outside an episode of illness, despite intake of ACE
                  inhibitors; mean systolic blood pressure should be under 130 mmHg and mean
                  diastolic blood pressure under 85 mmHg, when measured at home with ambulatory BP
                  monitoring

               -  Moderate or severe non-proliferative or proliferative retinopathy

               -  Hypoglycemic unawareness

          -  Cooperative and reliable patient giving informed consent by signature

        Exclusion Criteria:

          -  Smoker

          -  EBV antibody negativity

          -  HIV 1 &amp; 2 antibody positivity

          -  CMV IgM positivity

          -  Plasma creatinine ≥ 2 mg/dl and/or albuminuria ≥1000 mg/24 hrs

          -  History of thrombosis or pulmonary embolism

          -  History of malignancy, tuberculosis or chronic viral hepatitis

          -  History of any other serious illness which could be relevant for the protocol

          -  Presence of HLA antibodies

          -  Blood donation within one month prior to screening or during the study

          -  Symptoms and/or signs of infection, particularly (present or past) endocarditis,
             osteomyelitis, past tuberculosis with requirement for therapy

          -  Any history of hepatic or neoplastic disease

          -  Any history of renal disease (except diabetes)

          -  Abnormal liver function tests and /or NMR of liver

          -  Hemoglobinopathy

          -  History of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose additional risks to the patient

          -  Pregnancy or use of inadequate contraception by female patients of childbearing
             potential

          -  Use of illicit drugs or overconsumption of alcohol (&gt; 3 beers/day) or history of drug
             or alcohol abuse

          -  Being legally incapacitated, having significant emotional problems at the time of the
             study, or having a history of psychiatric disorders

          -  Having received antidepressant medications during the last 6 months

          -  Having participated the last 12 months or participating in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Keymeulen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Keymeulen, MD PhD</last_name>
    <phone>+32 2 477 61 11</phone>
    <email>bart.keymeulen@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart Keymeulen, MD Phd</last_name>
    <email>bart.keymeulen@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe De Block, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe de Block, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Keymeulen, MD PhD</last_name>
      <phone>+32 2 477 61 11</phone>
      <email>bart.keymeulen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Keymeulen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Crenier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Crenier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Gillard, MD PhD</last_name>
      <phone>+32 16 34 85 54</phone>
      <email>pieter.gillard@uz.kuleuven.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Da Hae Lee, MD</last_name>
      <phone>+32 16 34 23 98</phone>
      <email>dahae.lee@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Pieter Gillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Mathieu, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, Ysebaert D, Roep B, Vandemeulebroucke E, Marichal M, In 't Veld P, Bogdani M, Hendrieckx C, Gorus F, Ling Z, van Rood J, Pipeleers D. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17444-9. Epub 2006 Nov 7.</citation>
    <PMID>17090674</PMID>
  </reference>
  <reference>
    <citation>Movahedi B, Keymeulen B, Lauwers MH, Goes E, Cools N, Delvaux G. Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transpl Int. 2003 Mar;16(3):186-90. Epub 2003 Feb 15.</citation>
    <PMID>12664214</PMID>
  </reference>
  <reference>
    <citation>Maleux G, Gillard P, Keymeulen B, Pipeleers D, Ling Z, Heye S, Thijs M, Mathieu C, Marchal G. Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. J Vasc Interv Radiol. 2005 Dec;16(12):1693-7.</citation>
    <PMID>16371537</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <last_update_submitted>December 27, 2013</last_update_submitted>
  <last_update_submitted_qc>December 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ-VUB</investigator_affiliation>
    <investigator_full_name>Bart Keymeulen</investigator_full_name>
    <investigator_title>UZ Brussels</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus type 1</keyword>
  <keyword>pancreatic beta cell</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

